miR-184 represses β-catenin and behaves as a skin tumor suppressor
Cell Death & Disease · 2024
DOI: 10.1038/s41419-024-06554-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Death & Disease, 2024. Verfasst von Lubov Turovsky und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion -…. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, MicroRNAs, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Cancer Association (ICA).
Abstract (Originalsprache)
miR-184-knockout mice display perturbed epidermal stem cell differentiation. However, the potential role of miR-184 in skin pathology is unclear. Here, we report that miR-184 controls epidermal stem cell dynamics and that miR-184 ablation enhances skin carcinogenesis in mice. In agreement, repression of miR-184 in human squamous cell carcinoma (SCC) enhances neoplastic hallmarks of human SCC cells in vitro and tumor development in vivo. Characterization of miR-184-regulatory network, suggests that miR-184 inhibits pro-oncogenic pathways, cell proliferation, and epithelial to mesenchymal transformation. Of note, depletion of miR-184 enhances the levels of β-catenin under homeostasis and following experimental skin carcinogenesis. Finally, the repression of β-catenin by miR-184, inhibits the neoplastic phenotype of SCC cells. Taken together, miR-184 behaves as an epidermal tumor suppressor, and may provide a potentially useful target for skin SCC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, 31096, Israel.
- Skin Cancer Research lab, Clinical research institute (CRIR), Rambam Health Care Campus, Haifa, 31096, Israel.
- Cell Biology and Cancer Science, The Ruth and Bruce Rappaport Faculty of Medicine, Technion Integrated Cancer Center, Technion Israel Institute of Technology, Haifa, 31096, Israel.
- Université de Paris Cité, INSERM U1138, Centre des Cordeliers, Paris, France.
- Skin Cancer Research lab, Clinical research institute (CRIR), Rambam Health Care Campus, Haifa, 31096, Israel. emily@technion.ac.il.
- Cell Biology and Cancer Science, The Ruth and Bruce Rappaport Faculty of Medicine, Technion Integrated Cancer Center, Technion Israel Institute of Technology, Haifa, 31096, Israel. emily@technion.ac.il.
ORCID-Profile: Ghazal Kheshaiboun, Ruby Shalom-Feuerstein, Emily Avitan-Hersh
Förderung
- Israel Cancer Association (ICA)
Zitieren
APA
Turovsky, L., Kheshaiboun, G., Yassen, G., Nagosa, S., Boyango, I., Amitai-Lange, A., Bhattacharya, S., Ilan, N., Vlodavsky, I., Aberdam, D., Shalom-Feuerstein, R., & Avitan-Hersh, E. (2024). miR-184 represses β-catenin and behaves as a skin tumor suppressor. Cell Death & Disease. https://doi.org/10.1038/s41419-024-06554-4
Vancouver
Turovsky L, Kheshaiboun G, Yassen G, Nagosa S, Boyango I, Amitai-Lange A, et al. miR-184 represses β-catenin and behaves as a skin tumor suppressor. Cell Death & Disease. 2024. doi:10.1038/s41419-024-06554-4
BibTeX
@article{Turovsky2024,
author = {Turovsky, Lubov and Kheshaiboun, Ghazal and Yassen, Gharam and Nagosa, Sara and Boyango, Ilanit and Amitai-Lange, Aya and Bhattacharya, Swarnabh and Ilan, Neta and Vlodavsky, Israel and Aberdam, Daniel and Shalom-Feuerstein, Ruby and Avitan-Hersh, Emily},
title = {miR-184 represses β-catenin and behaves as a skin tumor suppressor},
journal = {Cell Death & Disease},
year = {2024},
doi = {10.1038/s41419-024-06554-4}
}
EUVIMED